Surprisingly, recent studies have demonstrated that the addition of LDL cholesterol increased activation of PI3K/AKT signaling, which coincided with reduced antitumor therapy such as sunitinib against ccRCC (Naito et al., 2017; Makhov et al., 2018). Here, AKT1 is linked to nonpapillary renal cell carcinoma.